Video Shorts

0:57
Highlighting the Role of MRD Testing in Breast Oncology
a month ago
by
Priya Rastogi, MD

0:41
Exploring the Potential Role of Detalimogene Voraplasmid in NMIBC
a month ago
by
Ashish M. Kamat, MD

1:05
The Potential of In Vivo CAR T-Cell Therapy in Multiple Myeloma
a month ago
by
Andrew Spencer, MBBS, FRACP, FRCPA, DM

0:46
Spotlighting the Potential Benefits of the SERENA-6 Trial Design in Breast Cancer
a month ago
by
Adam M. Brufsky, MD, PhD

1:40
Examining the Cognitive Effects of Darolutamide vs Enzalutamide in Prostate Cancer
a month ago
by
Alicia Morgans, MD, MPH, FASCO

0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Manish A. Shah, MD
a month ago
by
Jonathan Lee, MD, MSc

0:57
The Significance of the phase 3 frontMIND Data in High-Risk DLBCL
2 months ago
by
Bhavana Bhatnagar, DO

0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Sean Dougherty, MD
2 months ago
by
Jonathan Lee, MD, MSc

0:50
Evaluating the Effect of Response Depth on Treatment Outcomes in DESTINY-Breast09
2 months ago
by
Sara M. Tolaney, MD, MPH

0:49
Assessing Giredestrant-Based Therapy in ER+, HER2-Negative Advanced/Metastatic Breast Cancer
2 months ago
by
Mabel Mardones, MD

3:45
Exploring Notable Posters at the 2026 ASCO Annual Meeting
2 months ago
by
Chinmay Jani, MD

0:58
What Were the Biggest News at the 2026 ASCO Annual Meeting?
2 months ago
by
Joaquim Bellmunt, MD, PhD

0:48
Highlighting the Potential Role of Emi-Le in Aggressive ACC Management
2 months ago
by
Glenn J. Hanna, MD

0:37
Examining the Role of Robotics in Prostate Cancer
2 months ago
by
David Chen, MD

1:05
Potential Applications for Tumor-Informed ctDNA Deep Sequencing in Osteosarcoma
2 months ago
by
R. Lor Randall, MD, FACS

0:39
The Evaluation of HER3-DXd in Breast Cancer
2 months ago
by
Virginia G. Kaklamani, MD, DSc

1:10
What to Know About Toxicity Management With Zanidatamab Regimens From HERIZON-GEA-01
2 months ago
by
Geoffrey Y. Ku, MD

1:27
Examining Subgroup Data From PSMAaddition in mHSPC
2 months ago
by
Fred Saad, CQ, MD, FRCS, FCAHS

1:27
What Were the Most Notable News in Bladder Cancer at AUA 2026?
2 months ago
by
Mark D. Tyson, II, MD, MPH

0:32
Unpacking Patient Reported Outcome Data From IMvigor011 in Bladder Cancer
2 months ago
by
Joaquim Bellmunt, MD, PhD

1:10
HERIZON-GEA-01 Subgroup Analysis Supports Broad Benefit With Zanidatamab Regimen
2 months ago
by
Geoffrey Y. Ku, MD

2:32
MonumenTAL-3 Leads Key Myeloma Data Set To Emerge at EHA 2026
2 months ago
by
Rahul Banerjee, MD

0:55
What Were Some of the Notable Takeaways From the 2026 ASCO Annual Meeting?
2 months ago
by
Ravi B. Parikh, MD, MPP, FACP

1:53
Highlighting Brain Cancer Radiation Strategies and Needs for World Brain Tumor Day
2 months ago
by
Raj Singh, MD

1:30
Daraxonrasib Represents a Major Breakthrough for Pancreatic Cancer Care
2 months ago
by
Tanios S. Bekaii-Saab, MD

1:11
Unpacking the NEXUS-01 Data in Bladder Cancer
2 months ago
by
Gopa Iyer, MD

1:00
RASolute 302 Read Out Marks An Exciting New Chapter in Pancreatic Cancer Care
2 months ago
by
Vincent J. Picozzi, MD

0:50
Aglatimagene Besadenovec Emerges in Prostate Cancer
2 months ago
by
Mark Garzotto, MD

1:07
Giants of Cancer Care 2026
2 months ago
by
Jonathan Lee, MD, MSc(+1 more)

3:51
Recapping the ASCO 2026 OncLive Fellows Forum: Lung Cancer
2 months ago
by
Chinmay Jani, MD
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
2
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
3
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
4
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
5
